CytomX Therapeutics, Inc. (CTMX)

NASDAQ: CTMX · IEX Real-Time Price · USD
2.70
+0.02 (0.75%)
At close: Jan 31, 2023, 4:00 PM
2.66
-0.04 (-1.48%)
Pre-market: Feb 1, 2023, 6:18 AM EST
0.75%
Market Cap 178.43M
Revenue (ttm) 71.94M
Net Income (ttm) -97.59M
Shares Out 66.08M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 924,723
Open 2.63
Previous Close 2.68
Day's Range 2.63 - 2.74
52-Week Range 1.17 - 4.73
Beta 0.40
Analysts Hold
Price Target 2.88 (+6.67%)
Earnings Date Feb 27, 2023

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gas... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2015
Employees 174
Stock Exchange NASDAQ
Ticker Symbol CTMX
Full Company Profile

Financial Performance

In 2021, CTMX's revenue was $69.57 million, a decrease of -30.68% compared to the previous year's $100.36 million. Losses were -$83.61 million, 154.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for CTMX stock is "Hold." The 12-month stock price forecast is $2.88, which is an increase of 6.67% from the latest price.

Price Target
$2.88
(6.67% upside)
Analyst Consensus: Hold
Stock Forecasts

News

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX-

6 days ago - GlobeNewsWire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

2 weeks ago - GlobeNewsWire

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

Other symbols: MRNA
3 weeks ago - Zacks Investment Research

CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal

On a resoundingly positive Friday for the market, CytomX Therapeutics (NASDAQ: CTMX) is providing a large portion of the fireworks. Specifically, CTMX stock skyrocketed more than 50% before settling ...

Other symbols: MRNA
3 weeks ago - InvestorPlace

CytomX shares surge more than 50% on Moderna partnership

CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares ...

Other symbols: MRNA
3 weeks ago - Market Watch

Moderna signs $35 million deal with cancer drug developer CytomX

Moderna Inc on Thursday announced a $35 million licensing deal with cancer-focused drug developer CytomX Therapeutics to work on messenger RNA-based therapies for a wide range of diseases.

Other symbols: MRNA
3 weeks ago - Reuters

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront...

Other symbols: MRNA
3 weeks ago - Accesswire

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions

3 weeks ago - GlobeNewsWire

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to dete...

3 weeks ago - GlobeNewsWire

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it...

1 month ago - GlobeNewsWire

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Se...

1 month ago - GlobeNewsWire

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) --  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that P...

1 month ago - GlobeNewsWire

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

2 months ago - Zacks Investment Research

Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?

CytomX Therapeutics (NASDAQ: CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN). This strategic partnership will see the two compa...

2 months ago - InvestorPlace

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody ® and Regeneron's Veloci-Bi ® platforms -

2 months ago - GlobeNewsWire

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody® and Regeneron's Veloci-Bi ® platforms CytomX to receive $30 million upfr...

Other symbols: REGN
2 months ago - PRNewsWire

CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

- Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 -

3 months ago - GlobeNewsWire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is anticipated in the second half of 2023 -

3 months ago - GlobeNewsWire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Se...

3 months ago - GlobeNewsWire

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it...

3 months ago - GlobeNewsWire

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249

- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb -- BMS-986249 Phase 2 study ongoing -

5 months ago - GlobeNewsWire

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.78% and 1.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 -

6 months ago - GlobeNewsWire